STOCK TITAN

[8-K] 180 Life Sciences Corp. Warrant Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Lexeo Therapeutics (Nasdaq: LXEO) has filed a Rule 424(b)(3) prospectus to register up to 41,630,514 common shares for resale by investors that participated in a May 28 2025 private placement. The registered shares comprise 20.8 million outstanding shares plus 20.8 million shares underlying pre-funded ($0.0001 strike, no expiry) and common warrants ($2.82 strike, expiring May 28 2029>). The placement raised ≈$80 million at $2.8825 per share/unit; warrant exercises could generate an additional $39.1 million in cash. Lexeo will receive no proceeds from secondary sales but will cover registration expenses.

The capital, together with a recently redeployed $20 million from pre-clinical programs and a $75 million unused ATM facility, is expected to fund operations into 2028 and accelerate initiation of a registrational study for lead candidate LX2006 by early 2026.

Pipeline highlights

  • LX2006 (AAVrh10 gene therapy for Friedreich ataxia cardiomyopathy) – Phase 1/2 interim data (Apr 2025, n=16) showed dose-responsive increases in frataxin protein and improvements in cardiac biomarkers (LV mass index, lateral wall thickness, hs-troponin I) and functional measures (mFARS, KCCQ-12). FDA has agreed to an accelerated-approval pathway using LV mass index and frataxin expression as co-primary endpoints.
  • LX2020 (PKP2 arrhythmogenic cardiomyopathy) – Phase 1/2 HEROIC-PKP2 (n=6) demonstrated 71-115 % PKP2 protein increases in two biopsied patients and a 67 % PVC reduction in the first six-month follow-up. Interim efficacy read-out is expected 2H-2025.

The company remains an emerging growth and smaller reporting company, permitting scaled disclosure under U.S. securities laws. On June 30 2025 LXEO closed at $4.02.

Lexeo Therapeutics (Nasdaq: LXEO) ha presentato un prospetto ai sensi della Rule 424(b)(3) per registrare fino a 41.630.514 azioni ordinarie da rivendere da parte degli investitori che hanno partecipato a un collocamento privato il 28 maggio 2025. Le azioni registrate comprendono 20,8 milioni di azioni in circolazione più 20,8 milioni di azioni sottostanti warrant pre-finanziati ($0,0001 strike, senza scadenza) e warrant ordinari ($2,82 strike, scadenza 28 maggio 2029). Il collocamento ha raccolto circa $80 milioni a $2,8825 per azione/unità; l’esercizio dei warrant potrebbe generare ulteriori $39,1 milioni in contanti. Lexeo non riceverà proventi dalle vendite secondarie ma coprirà le spese di registrazione.

Il capitale, insieme a un recente riutilizzo di $20 milioni provenienti da programmi preclinici e a una linea ATM inutilizzata da $75 milioni, dovrebbe finanziare le operazioni fino al 2028 e accelerare l’avvio di uno studio registrativo per il candidato principale LX2006 entro l’inizio del 2026.

Punti salienti della pipeline

  • LX2006 (terapia genica AAVrh10 per la cardiomiopatia da atassia di Friedreich) – Dati intermedi di fase 1/2 (aprile 2025, n=16) hanno mostrato aumenti dose-risposta della proteina frataxina e miglioramenti nei biomarcatori cardiaci (indice di massa ventricolare sinistra, spessore parete laterale, hs-troponina I) e nelle misure funzionali (mFARS, KCCQ-12). La FDA ha concordato un percorso di approvazione accelerata usando indice di massa ventricolare sinistra ed espressione di frataxina come endpoint co-primari.
  • LX2020 (cardiomiopatia aritmogena PKP2) – La fase 1/2 HEROIC-PKP2 (n=6) ha dimostrato aumenti del 71-115% della proteina PKP2 in due pazienti biopsiati e una riduzione del 67% delle PVC nel primo follow-up di sei mesi. La lettura intermedia sull’efficacia è prevista per la seconda metà del 2025.

L’azienda rimane una emerging growth e smaller reporting company, permettendo una disclosure ridotta secondo le normative statunitensi sui titoli. Il 30 giugno 2025 LXEO ha chiuso a $4,02.

Lexeo Therapeutics (Nasdaq: LXEO) ha presentado un prospecto bajo la Regla 424(b)(3) para registrar hasta 41,630,514 acciones ordinarias para la reventa por parte de inversores que participaron en una colocación privada el 28 de mayo de 2025. Las acciones registradas comprenden 20,8 millones de acciones en circulación más 20,8 millones de acciones subyacentes a warrants prefinanciados ($0.0001 strike, sin vencimiento) y warrants ordinarios ($2.82 strike, vencimiento 28 de mayo de 2029). La colocación recaudó aproximadamente $80 millones a $2.8825 por acción/unidad; el ejercicio de warrants podría generar $39.1 millones adicionales en efectivo. Lexeo no recibirá ingresos por ventas secundarias pero cubrirá los gastos de registro.

El capital, junto con una reciente reasignación de $20 millones de programas preclínicos y una línea ATM no utilizada de $75 millones, se espera que financie las operaciones hasta 2028 y acelere el inicio de un estudio registracional para el candidato principal LX2006 a principios de 2026.

Aspectos destacados de la cartera

  • LX2006 (terapia génica AAVrh10 para la miocardiopatía por ataxia de Friedreich) – Datos interinos de fase 1/2 (abril 2025, n=16) mostraron aumentos dependientes de la dosis en la proteína frataxina y mejoras en biomarcadores cardíacos (índice de masa ventricular izquierda, grosor de pared lateral, hs-troponina I) y medidas funcionales (mFARS, KCCQ-12). La FDA ha acordado una vía de aprobación acelerada utilizando el índice de masa ventricular izquierda y la expresión de frataxina como puntos finales co-primarios.
  • LX2020 (miocardiopatía arritmogénica PKP2) – La fase 1/2 HEROIC-PKP2 (n=6) demostró aumentos del 71-115% de la proteína PKP2 en dos pacientes biopsiados y una reducción del 67% de PVC en el primer seguimiento de seis meses. Se espera una lectura interina de eficacia en la segunda mitad de 2025.

La compañía sigue siendo una emerging growth y smaller reporting company, lo que permite una divulgación escalada bajo las leyes de valores de EE.UU. Al 30 de junio de 2025, LXEO cerró en $4.02.

Lexeo Therapeutics (Nasdaq: LXEO)는 2025년 5월 28일에 진행된 사모 투자에 참여한 투자자들이 재판매할 수 있도록 최대 41,630,514 보통주를 등록하기 위해 Rule 424(b)(3) 설명서를 제출했습니다. 등록된 주식은 2,080만 주의 유통 주식과 프리펀드($0.0001 행사가, 만기 없음) 및 보통 워런트($2.82 행사가, 2029년 5월 28일 만료)에 해당하는 2,080만 주를 포함합니다. 이번 배정으로 주당 $2.8825에 약 $8000만이 조달되었으며, 워런트 행사로 추가로 $3,910만의 현금이 발생할 수 있습니다. Lexeo는 2차 판매로부터 수익을 받지 않지만 등록 비용은 부담할 예정입니다.

이 자본금은 최근 전임상 프로그램에서 재배치된 $2,000만과 미사용 ATM 시설 $7,500만과 함께 2028년까지 운영 자금을 지원하고, 2026년 초까지 주력 후보물질 LX2006의 등록 연구 개시를 가속화할 것으로 예상됩니다.

파이프라인 주요 내용

  • LX2006 (프리드라이히 운동실조증 심근병증을 위한 AAVrh10 유전자 치료제) – 1/2상 중간 데이터(2025년 4월, n=16)는 프라탁신 단백질의 용량 반응 증가와 심장 바이오마커(좌심실 질량 지수, 측벽 두께, hs-트로포닌 I) 및 기능 지표(mFARS, KCCQ-12)의 개선을 보여주었습니다. FDA는 좌심실 질량 지수와 프라탁신 발현을 공동 주요 평가변수로 하는 가속 승인 경로에 동의했습니다.
  • LX2020 (PKP2 부정맥 심근병증) – 1/2상 HEROIC-PKP2(n=6)는 생검한 두 환자에서 PKP2 단백질이 71-115% 증가했으며, 첫 6개월 추적 관찰에서 PVC가 67% 감소했습니다. 중간 효능 결과는 2025년 하반기에 발표될 예정입니다.

회사는 여전히 emerging growthsmaller reporting company로서 미국 증권법에 따라 간소화된 공시를 허용받고 있습니다. 2025년 6월 30일 LXEO의 종가는 $4.02였습니다.

Lexeo Therapeutics (Nasdaq : LXEO) a déposé un prospectus en vertu de la règle 424(b)(3) pour enregistrer jusqu’à 41 630 514 actions ordinaires en vue de leur revente par des investisseurs ayant participé à un placement privé le 28 mai 2025. Les actions enregistrées comprennent 20,8 millions d’actions en circulation ainsi que 20,8 millions d’actions sous-jacentes à des bons de souscription préfinancés (0,0001 $ prix d’exercice, sans échéance) et ordinaires (2,82 $ prix d’exercice, échéance le 28 mai 2029). Le placement a levé environ 80 millions de dollars au prix de 2,8825 $ par action/unité ; l’exercice des bons pourrait générer 39,1 millions de dollars supplémentaires en liquidités. Lexeo ne recevra aucun produit des ventes secondaires mais prendra en charge les frais d’enregistrement.

Le capital, ainsi qu’un récent réinvestissement de 20 millions de dollars issus de programmes précliniques et une facilité ATM inutilisée de 75 millions de dollars, devrait financer les opérations jusqu’en 2028 et accélérer le lancement d’une étude d’enregistrement pour le candidat principal LX2006 début 2026.

Points forts de la pipeline

  • LX2006 (thérapie génique AAVrh10 pour la cardiomyopathie liée à l’ataxie de Friedreich) – Les données intermédiaires de phase 1/2 (avril 2025, n=16) ont montré des augmentations dose-dépendantes de la protéine frataxine et des améliorations des biomarqueurs cardiaques (indice de masse ventriculaire gauche, épaisseur de la paroi latérale, hs-troponine I) ainsi que des mesures fonctionnelles (mFARS, KCCQ-12). La FDA a accepté une voie d’approbation accélérée utilisant l’indice de masse ventriculaire gauche et l’expression de la frataxine comme critères co-primaires.
  • LX2020 (cardiomyopathie arythmogène PKP2) – La phase 1/2 HEROIC-PKP2 (n=6) a montré des augmentations de 71 à 115 % de la protéine PKP2 chez deux patients biopsiés et une réduction de 67 % des PVC lors du premier suivi de six mois. Une première évaluation de l’efficacité est attendue au second semestre 2025.

L’entreprise reste une emerging growth et une smaller reporting company, ce qui permet une divulgation réduite selon la réglementation américaine sur les valeurs mobilières. Le 30 juin 2025, LXEO a clôturé à 4,02 $.

Lexeo Therapeutics (Nasdaq: LXEO) hat einen Rule 424(b)(3) Prospekt eingereicht, um bis zu 41.630.514 Stammaktien für den Weiterverkauf durch Investoren zu registrieren, die an einer Privatplatzierung am 28. Mai 2025 teilgenommen haben. Die registrierten Aktien umfassen 20,8 Millionen ausstehende Aktien sowie 20,8 Millionen Aktien, die durch vorfinanzierte Warrants ($0,0001 Ausübungspreis, ohne Ablaufdatum) und gewöhnliche Warrants ($2,82 Ausübungspreis, Ablauf 28. Mai 2029) gedeckt sind. Die Platzierung brachte ca. $80 Millionen bei einem Preis von $2,8825 pro Aktie/Einheit ein; die Ausübung der Warrants könnte zusätzliche $39,1 Millionen in bar generieren. Lexeo erhält keine Erlöse aus Sekundärverkäufen, übernimmt jedoch die Registrierungskosten.

Das Kapital, zusammen mit kürzlich umgeschichteten $20 Millionen aus präklinischen Programmen und einer ungenutzten ATM-Fazilität von $75 Millionen, soll die Geschäftstätigkeit bis 2028 finanzieren und den Start einer Zulassungsstudie für den Hauptkandidaten LX2006 bis Anfang 2026 beschleunigen.

Pipeline-Highlights

  • LX2006 (AAVrh10 Gentherapie für Friedreich-Ataxie-Kardiomyopathie) – Zwischenberichte der Phase 1/2 (April 2025, n=16) zeigten dosisabhängige Anstiege des Frataxin-Proteins und Verbesserungen bei kardialen Biomarkern (LV-Masse-Index, laterale Wanddicke, hs-Troponin I) sowie funktionellen Messungen (mFARS, KCCQ-12). Die FDA hat einem beschleunigten Zulassungsweg zugestimmt, der den LV-Masse-Index und die Frataxin-Expression als Co-Primärendpunkte nutzt.
  • LX2020 (PKP2 arrhythmogene Kardiomyopathie) – Die Phase 1/2 HEROIC-PKP2 (n=6) zeigte eine Erhöhung des PKP2-Proteins um 71-115 % bei zwei biopsierten Patienten und eine Reduktion der PVC um 67 % im ersten sechsmonatigen Follow-up. Ein Zwischenbericht zur Wirksamkeit wird für die zweite Hälfte 2025 erwartet.

Das Unternehmen bleibt ein emerging growth und smaller reporting company, was eine reduzierte Offenlegung nach US-Wertpapiergesetzen erlaubt. Am 30. Juni 2025 schloss LXEO bei $4,02.

Positive
  • $80 million private placement completed at $2.8825 per share, materially strengthening cash position.
  • Potential for an additional $39.1 million in cash if common warrants are exercised at $2.82.
  • Cash plus redeployed $20 million expected to fund operations into 2028, lowering near-term financing risk.
  • FDA alignment on accelerated-approval pathway for LX2006 with clearly defined co-primary endpoints.
  • Interim Phase 1/2 data for LX2006 show dose-responsive frataxin expression and cardiac biomarker improvement.
  • LX2020 early data indicate 71-115 % PKP2 protein increase and arrhythmic improvements, with good tolerability.
Negative
  • Registration covers 41.6 million shares—about 125 % of current shares outstanding—creating potential dilution and selling pressure.
  • Workforce reduction of ≈15 % and shelving of pre-clinical projects suggest constrained resources and pipeline narrowing.
  • Company qualifies as an emerging growth and smaller reporting company, offering investors reduced disclosure and auditor attestation.
  • All product candidates remain in Phase 1/2; there is no revenue and high clinical and regulatory risk.

Insights

TL;DR $80 M cash plus warrant optionality extends runway to 2028 and supports LX2006 accelerated-approval path; share overhang tempers upside.

The resale filing itself is routine, yet it crystallises the positive financing achieved in May 2025. The private placement added ~2.4 years of liquidity at a modest 5 % premium to the 30-day VWAP, and warrants could deliver a further $39 M at a small premium to placement price, providing non-dilutive cash relative to current market. Operationally, Lexeo now has funds to complete SUNRISE-FA, prepare a pivotal study and progress LX2020 through proof-of-concept. The FDA’s agreement on LV mass index and frataxin expression as registrational endpoints materially de-risks LX2006 and could accelerate time-to-market, a rarity in cardiac gene therapy. Near-term catalysts include additional LX2006 biopsies, HEROIC-PKP2 efficacy data and potential warrant exercises if share price remains above $2.82.

TL;DR Large 41.6 M share overhang and 125 % potential dilution offset otherwise constructive cash extension; event viewed as neutral.

While fresh capital and regulatory momentum are favourable, the prospectus highlights considerable supply risk. The registered shares equal ~125 % of the 33.2 M shares outstanding as of March 31 2025; selling pressure from well-known biotech funds could constrain near-term appreciation. Beneficial-ownership caps (4.99-14.99 %) limit individual exercises but do not remove aggregate dilution once shares reach the market. Workforce cuts (15 %) and narrowed pipeline signal focused spending but underscore reliance on two early-stage assets with no commercial revenue. Overall impact on valuation is balanced: liquidity reduces financing risk, yet dilution and execution risk on LX2006/LX2020 remain high.

Lexeo Therapeutics (Nasdaq: LXEO) ha presentato un prospetto ai sensi della Rule 424(b)(3) per registrare fino a 41.630.514 azioni ordinarie da rivendere da parte degli investitori che hanno partecipato a un collocamento privato il 28 maggio 2025. Le azioni registrate comprendono 20,8 milioni di azioni in circolazione più 20,8 milioni di azioni sottostanti warrant pre-finanziati ($0,0001 strike, senza scadenza) e warrant ordinari ($2,82 strike, scadenza 28 maggio 2029). Il collocamento ha raccolto circa $80 milioni a $2,8825 per azione/unità; l’esercizio dei warrant potrebbe generare ulteriori $39,1 milioni in contanti. Lexeo non riceverà proventi dalle vendite secondarie ma coprirà le spese di registrazione.

Il capitale, insieme a un recente riutilizzo di $20 milioni provenienti da programmi preclinici e a una linea ATM inutilizzata da $75 milioni, dovrebbe finanziare le operazioni fino al 2028 e accelerare l’avvio di uno studio registrativo per il candidato principale LX2006 entro l’inizio del 2026.

Punti salienti della pipeline

  • LX2006 (terapia genica AAVrh10 per la cardiomiopatia da atassia di Friedreich) – Dati intermedi di fase 1/2 (aprile 2025, n=16) hanno mostrato aumenti dose-risposta della proteina frataxina e miglioramenti nei biomarcatori cardiaci (indice di massa ventricolare sinistra, spessore parete laterale, hs-troponina I) e nelle misure funzionali (mFARS, KCCQ-12). La FDA ha concordato un percorso di approvazione accelerata usando indice di massa ventricolare sinistra ed espressione di frataxina come endpoint co-primari.
  • LX2020 (cardiomiopatia aritmogena PKP2) – La fase 1/2 HEROIC-PKP2 (n=6) ha dimostrato aumenti del 71-115% della proteina PKP2 in due pazienti biopsiati e una riduzione del 67% delle PVC nel primo follow-up di sei mesi. La lettura intermedia sull’efficacia è prevista per la seconda metà del 2025.

L’azienda rimane una emerging growth e smaller reporting company, permettendo una disclosure ridotta secondo le normative statunitensi sui titoli. Il 30 giugno 2025 LXEO ha chiuso a $4,02.

Lexeo Therapeutics (Nasdaq: LXEO) ha presentado un prospecto bajo la Regla 424(b)(3) para registrar hasta 41,630,514 acciones ordinarias para la reventa por parte de inversores que participaron en una colocación privada el 28 de mayo de 2025. Las acciones registradas comprenden 20,8 millones de acciones en circulación más 20,8 millones de acciones subyacentes a warrants prefinanciados ($0.0001 strike, sin vencimiento) y warrants ordinarios ($2.82 strike, vencimiento 28 de mayo de 2029). La colocación recaudó aproximadamente $80 millones a $2.8825 por acción/unidad; el ejercicio de warrants podría generar $39.1 millones adicionales en efectivo. Lexeo no recibirá ingresos por ventas secundarias pero cubrirá los gastos de registro.

El capital, junto con una reciente reasignación de $20 millones de programas preclínicos y una línea ATM no utilizada de $75 millones, se espera que financie las operaciones hasta 2028 y acelere el inicio de un estudio registracional para el candidato principal LX2006 a principios de 2026.

Aspectos destacados de la cartera

  • LX2006 (terapia génica AAVrh10 para la miocardiopatía por ataxia de Friedreich) – Datos interinos de fase 1/2 (abril 2025, n=16) mostraron aumentos dependientes de la dosis en la proteína frataxina y mejoras en biomarcadores cardíacos (índice de masa ventricular izquierda, grosor de pared lateral, hs-troponina I) y medidas funcionales (mFARS, KCCQ-12). La FDA ha acordado una vía de aprobación acelerada utilizando el índice de masa ventricular izquierda y la expresión de frataxina como puntos finales co-primarios.
  • LX2020 (miocardiopatía arritmogénica PKP2) – La fase 1/2 HEROIC-PKP2 (n=6) demostró aumentos del 71-115% de la proteína PKP2 en dos pacientes biopsiados y una reducción del 67% de PVC en el primer seguimiento de seis meses. Se espera una lectura interina de eficacia en la segunda mitad de 2025.

La compañía sigue siendo una emerging growth y smaller reporting company, lo que permite una divulgación escalada bajo las leyes de valores de EE.UU. Al 30 de junio de 2025, LXEO cerró en $4.02.

Lexeo Therapeutics (Nasdaq: LXEO)는 2025년 5월 28일에 진행된 사모 투자에 참여한 투자자들이 재판매할 수 있도록 최대 41,630,514 보통주를 등록하기 위해 Rule 424(b)(3) 설명서를 제출했습니다. 등록된 주식은 2,080만 주의 유통 주식과 프리펀드($0.0001 행사가, 만기 없음) 및 보통 워런트($2.82 행사가, 2029년 5월 28일 만료)에 해당하는 2,080만 주를 포함합니다. 이번 배정으로 주당 $2.8825에 약 $8000만이 조달되었으며, 워런트 행사로 추가로 $3,910만의 현금이 발생할 수 있습니다. Lexeo는 2차 판매로부터 수익을 받지 않지만 등록 비용은 부담할 예정입니다.

이 자본금은 최근 전임상 프로그램에서 재배치된 $2,000만과 미사용 ATM 시설 $7,500만과 함께 2028년까지 운영 자금을 지원하고, 2026년 초까지 주력 후보물질 LX2006의 등록 연구 개시를 가속화할 것으로 예상됩니다.

파이프라인 주요 내용

  • LX2006 (프리드라이히 운동실조증 심근병증을 위한 AAVrh10 유전자 치료제) – 1/2상 중간 데이터(2025년 4월, n=16)는 프라탁신 단백질의 용량 반응 증가와 심장 바이오마커(좌심실 질량 지수, 측벽 두께, hs-트로포닌 I) 및 기능 지표(mFARS, KCCQ-12)의 개선을 보여주었습니다. FDA는 좌심실 질량 지수와 프라탁신 발현을 공동 주요 평가변수로 하는 가속 승인 경로에 동의했습니다.
  • LX2020 (PKP2 부정맥 심근병증) – 1/2상 HEROIC-PKP2(n=6)는 생검한 두 환자에서 PKP2 단백질이 71-115% 증가했으며, 첫 6개월 추적 관찰에서 PVC가 67% 감소했습니다. 중간 효능 결과는 2025년 하반기에 발표될 예정입니다.

회사는 여전히 emerging growthsmaller reporting company로서 미국 증권법에 따라 간소화된 공시를 허용받고 있습니다. 2025년 6월 30일 LXEO의 종가는 $4.02였습니다.

Lexeo Therapeutics (Nasdaq : LXEO) a déposé un prospectus en vertu de la règle 424(b)(3) pour enregistrer jusqu’à 41 630 514 actions ordinaires en vue de leur revente par des investisseurs ayant participé à un placement privé le 28 mai 2025. Les actions enregistrées comprennent 20,8 millions d’actions en circulation ainsi que 20,8 millions d’actions sous-jacentes à des bons de souscription préfinancés (0,0001 $ prix d’exercice, sans échéance) et ordinaires (2,82 $ prix d’exercice, échéance le 28 mai 2029). Le placement a levé environ 80 millions de dollars au prix de 2,8825 $ par action/unité ; l’exercice des bons pourrait générer 39,1 millions de dollars supplémentaires en liquidités. Lexeo ne recevra aucun produit des ventes secondaires mais prendra en charge les frais d’enregistrement.

Le capital, ainsi qu’un récent réinvestissement de 20 millions de dollars issus de programmes précliniques et une facilité ATM inutilisée de 75 millions de dollars, devrait financer les opérations jusqu’en 2028 et accélérer le lancement d’une étude d’enregistrement pour le candidat principal LX2006 début 2026.

Points forts de la pipeline

  • LX2006 (thérapie génique AAVrh10 pour la cardiomyopathie liée à l’ataxie de Friedreich) – Les données intermédiaires de phase 1/2 (avril 2025, n=16) ont montré des augmentations dose-dépendantes de la protéine frataxine et des améliorations des biomarqueurs cardiaques (indice de masse ventriculaire gauche, épaisseur de la paroi latérale, hs-troponine I) ainsi que des mesures fonctionnelles (mFARS, KCCQ-12). La FDA a accepté une voie d’approbation accélérée utilisant l’indice de masse ventriculaire gauche et l’expression de la frataxine comme critères co-primaires.
  • LX2020 (cardiomyopathie arythmogène PKP2) – La phase 1/2 HEROIC-PKP2 (n=6) a montré des augmentations de 71 à 115 % de la protéine PKP2 chez deux patients biopsiés et une réduction de 67 % des PVC lors du premier suivi de six mois. Une première évaluation de l’efficacité est attendue au second semestre 2025.

L’entreprise reste une emerging growth et une smaller reporting company, ce qui permet une divulgation réduite selon la réglementation américaine sur les valeurs mobilières. Le 30 juin 2025, LXEO a clôturé à 4,02 $.

Lexeo Therapeutics (Nasdaq: LXEO) hat einen Rule 424(b)(3) Prospekt eingereicht, um bis zu 41.630.514 Stammaktien für den Weiterverkauf durch Investoren zu registrieren, die an einer Privatplatzierung am 28. Mai 2025 teilgenommen haben. Die registrierten Aktien umfassen 20,8 Millionen ausstehende Aktien sowie 20,8 Millionen Aktien, die durch vorfinanzierte Warrants ($0,0001 Ausübungspreis, ohne Ablaufdatum) und gewöhnliche Warrants ($2,82 Ausübungspreis, Ablauf 28. Mai 2029) gedeckt sind. Die Platzierung brachte ca. $80 Millionen bei einem Preis von $2,8825 pro Aktie/Einheit ein; die Ausübung der Warrants könnte zusätzliche $39,1 Millionen in bar generieren. Lexeo erhält keine Erlöse aus Sekundärverkäufen, übernimmt jedoch die Registrierungskosten.

Das Kapital, zusammen mit kürzlich umgeschichteten $20 Millionen aus präklinischen Programmen und einer ungenutzten ATM-Fazilität von $75 Millionen, soll die Geschäftstätigkeit bis 2028 finanzieren und den Start einer Zulassungsstudie für den Hauptkandidaten LX2006 bis Anfang 2026 beschleunigen.

Pipeline-Highlights

  • LX2006 (AAVrh10 Gentherapie für Friedreich-Ataxie-Kardiomyopathie) – Zwischenberichte der Phase 1/2 (April 2025, n=16) zeigten dosisabhängige Anstiege des Frataxin-Proteins und Verbesserungen bei kardialen Biomarkern (LV-Masse-Index, laterale Wanddicke, hs-Troponin I) sowie funktionellen Messungen (mFARS, KCCQ-12). Die FDA hat einem beschleunigten Zulassungsweg zugestimmt, der den LV-Masse-Index und die Frataxin-Expression als Co-Primärendpunkte nutzt.
  • LX2020 (PKP2 arrhythmogene Kardiomyopathie) – Die Phase 1/2 HEROIC-PKP2 (n=6) zeigte eine Erhöhung des PKP2-Proteins um 71-115 % bei zwei biopsierten Patienten und eine Reduktion der PVC um 67 % im ersten sechsmonatigen Follow-up. Ein Zwischenbericht zur Wirksamkeit wird für die zweite Hälfte 2025 erwartet.

Das Unternehmen bleibt ein emerging growth und smaller reporting company, was eine reduzierte Offenlegung nach US-Wertpapiergesetzen erlaubt. Am 30. Juni 2025 schloss LXEO bei $4,02.

false 0001690080 0001690080 2025-07-01 2025-07-01 0001690080 ATNF:CommonStockParValue0.0001PerShareMember 2025-07-01 2025-07-01 0001690080 ATNF:WarrantsToPurchaseSharesOfCommonStockMember 2025-07-01 2025-07-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): July 1, 2025

 

180 LIFE SCIENCES CORP.

(Exact Name of Registrant as Specified in Charter)

 

Delaware   001-38105   90-1890354
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)   (IRS Employer
Identification No.)

 

3000 El Camino Real, Bldg. 4, Suite 200

Palo Alto, CA

  94306
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650507-0669

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.0001 per share   ATNF   The NASDAQ Stock Market LLC
Warrants to purchase shares of Common Stock   ATNFW   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 

 

 

 

Item 8.01 Other Events

 

On July 1, 2025, 180 Life Sciences Corp. (the “Company”) issued a press release announcing the grant of a U.S. patent by the United States Patent and Trademark Office and the receipt by the Canadian Intellectual Property Office of a Notice of Allowance for another patent application.

 

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits. 

 

Exhibit Number   Description
99.1   Press Release  dated July 1, 2025
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

Forward- Looking Statements

 

This Current Report on Form 8-K and Exhibit 99.1 attached contain forward-looking statements that are made pursuant to the safe harbor provisions within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Private Securities Litigation Reform Act, as amended. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, many of which are beyond our control, that may cause actual results or events to differ materially from those projected. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled “Risk Factors” and elsewhere in our Annual Reports on Form 10-K and in our other filings with the SEC, including, without limitation, our reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 1, 2025

 

  180 LIFE SCIENCES CORP.
   
  By:  /s/ Blair Jordan
    Name:  Blair Jordan
    Title: Chief Executive Officer

 

 

2

 

 

 

FAQ

Why is Lexeo (LXEO) registering 41.6 million shares?

The filing enables selling stockholders from the May 2025 $80 M private placement to resell their shares and warrant-related shares on Nasdaq.

How much cash did LXEO raise in the May 2025 private placement?

Lexeo received ≈$80 million in gross proceeds at $2.8825 per share/unit on May 28 2025.

What are the terms and potential proceeds of the warrants?

Pre-funded warrants are exercisable at $0.0001 with no expiry; common warrants are exercisable at $2.82 until May 28 2029, potentially adding $39.1 M in cash.

What is the clinical status of LX2006 for Friedreich ataxia cardiomyopathy?

Phase 1/2 interim data (Apr 2025) show increased frataxin protein and cardiac biomarker improvement; FDA has agreed to an accelerated-approval path with LV mass index and frataxin expression endpoints.

What early results have been reported for LX2020?

In HEROIC-PKP2, two biopsied patients showed 71-115 % PKP2 protein increases; one patient saw a 67 % PVC reduction; no serious safety signals to date.

How long is Lexeo’s cash runway after the transaction?

Management projects an operational runway into 2028, incorporating private-placement proceeds and $20 M of redeployed capital.
180 Life Sciences Corp

NASDAQ:ATNFW

ATNFW Rankings

ATNFW Latest News

ATNFW Latest SEC Filings

ATNFW Stock Data

5.19M
Biotechnology
Pharmaceutical Preparations
Link
United States
PALO ALTO